Insulin injection pens are the predominant devices for insulin delivery in Europe and Japan because of their ease of use and convenience. This study compared clinically relevant technical attributes of durable insulin pens that are important to people with diabetes, specifically functions relating to cartridge-fitting, dose-setting, and dose-delivery on NovoPen® 4, ClikStar®, HumaPen Luxura®, Itango®, and Biosulin® Pen.

Methods::

Frequency components and duration of audible clicks on dose setting and injection were measured using audio equipment when setting and delivering 20 IU of insulin. To assess cartridge-fitting torque, each pen was attached to a torque gauge via the attached needle, and torque was measured with each 180° turn as the cartridge was screwed into the body of the pen. Rotary torque of the dose-setting dial was measured when setting the dose to the maximum dose unit of the pen. Injection force was measured when delivering 20 IU at 5 mm/s in a vertical position and at a tilt of 14.7° from vertical.

Results::

Audible clicks on dose-setting and dose-delivery were most distinguishable on NovoPen 4, while NovoPen 4 and ClikStar had generally lower cartridge-fitting torque and injection (both vertical and angled) force values.

Conclusion::

Overall, the results showed that durable insulin pens such as NovoPen 4 have useful features related to assembly, dose-setting, and injection, which may facilitate ease of use for diabetes patients, particularly elderly patients and those with visual and/or manual dexterity impairments.

2004-01-01·Terapevticheskii arkhiv

[Experience of using biosulin P and biosulin H for the treatment of diabetes mellitus].

作者: Dedov, I I ; Balabolkin, M I

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde4区 · 医学

The Biosulin equivalence in standard therapy (BEST) study − a multicentre, open-label, non-randomised, interventional, observational study in subjects using Biosulin 30/70 for the treatment of insulin-dependent type 1 and type 2 diabetes mellitus

4区 · 医学

ArticleOA

作者: Daniela Tupy ; David Grant Segal ; Larry A Distiller

INTRODUCTION:

The need for more cost-effective insulin therapy is critical in reducing the burden on patients and health systems. Biosimilar insulins have the potential to dramatically lower healthcare costs by delivering insulin with a similar anti-glycaemic effect and adverse reaction profile.

OBJECTIVES:

The purpose of this study was to confirm equivalence in glycaemic outcomes and side-effect profiles between Biosulin 30/70 and other human premixed insulin preparations on the South African market in a clinical practice setting.

METHODS:

Subjects in this interventional, observational, multicentre, open-label, prospective study were switched from their existing human premix insulin (Actraphane, Humulin 30/70 or Insuman) to the study insulin Biosulin 30/70. The primary endpoint was the change in HbA1c from baseline to 6 months.

RESULTS:

Seventy-seven adult patients with type 1(n=18) or type 2 (n=59) diabetes were enrolled. The baseline HbA1c in the overall cohort was 7.9%, 8.0% at 3 months (p=0.50) and 7.6% at 6 months (p=0.14).There was a small increase in the total daily dose of insulin used in both the type 1 and type 2 cohort, from 0.62 to 0.65 units/kg/day (p=0.0004). There was no significant difference in weight in the study subjects during the 6-month period on Biosulin 30/70 (p=0.67).

CONCLUSION:

Biosulin 30/70 achieved at least equivalent glycaemic control to existing human premix insulins, with no reported new or severe adverse events. Increased use of biosimilar insulins has the potential for significant cost savings.

项与人胰岛素生物类似药(M J Biopharm Pvt Ltd.) 相关的新闻（医药）

2022-11-30

·PRNewswire

The Worldwide Insulin Industry is Projected to Reach $111.2 Billion by 2028

DUBLIN, Nov. 30, 2022 /PRNewswire/ -- The "Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Geography" report has been added to ResearchAndMarkets.com's offering. The insulin market is projected to grow from US$ 54,611.42 million in 2021 to US$ 111,213.73 million by 2028. It is expected to grow at a CAGR of 10.8 % from 2022 to 2028. The increase in the incidence of diabetes and rapid technological developments in insulin delivery devices by major players is expected to bolster the insulin market in the years to come. Additionally, the regeneration of the diabetic pancreas with advanced transplants is likely to emerge as a significant future trend in the insulin market from 2022 to 2028. However, the risks associated with insulin delivery devices hamper the overall market growth. In diabetic people, the pancreas does not produce enough insulin, or the body does not usually respond to the insulin, increasing the blood glucose level. Insulin is a hormone that helps in lowering blood sugar levels. Insulin therapy is often an essential part of diabetes treatment. It is made by the beta cells of the pancreas and released into the blood when glucose levels rise, for example, after eating. Insulin helps glucose get into the body cells, which can be used for energy or stored for future use. Different types of insulin available vary in how quickly and for how long they can control blood sugar. Insulin does not come in pill form as the digestive system would break it down before it could work. Insulin therapy is exhausting; however, it is an effective way of lowering blood sugar levels. Products with advanced insulin technology with more benefits are a major requirement in treating diabetes. There has been a rise in advancements in diabetes treatment over the past few years. As the prevalence of diabetes is increasing worldwide, the demand for advanced products is also boosting. The insulin market is expected to grow owing to an increase in the strategic efforts made by the industry players. The market players actively support their public and private research and academic institutes for increasing research activities. A few of the recent developments related to rapid technological advancement in the insulin market are mentioned below: In May 2022, Eli Lilly and Company received US FDA approval for its Mounjar (tirzepatide) once-weekly Glucose-Dependent Insulinotropic Polypeptide (GIP) and GLP-1 Glucagon-like Peptide-1 (GLP-1) receptor agonist for the treatment of adults with type 2 diabetes. The injection is decided to be available in 6 doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) as an auto-injector pen with a preattached hidden needle. Key Topics Covered: 1. Introduction 2. Insulin Market - Key Takeaways 3. Research Methodology 4. Insulin Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.2.1 North America- PEST Analysis 4.2.2 Europe- PEST Analysis 4.2.3 Asia Pacific- PEST Analysis 4.2.4 Middle East & Africa- PEST Analysis 4.2.5 South & Central America- PEST Analysis 4.2.6 Expert Opinion 5. Insulin Market- Key Market Dynamics 5.1 Market Drivers 5.1.1 Increase in Incidence of Diabetes 5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players 5.2 Market Restraints 5.2.1 Risks Associated with Insulin Delivery Devices 5.3 Market Opportunities 5.3.1 Insufficient Competition from Biosimilars 5.4 Future Trends 5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants 5.5 Impact Analysis 6. Insulin Market- Global Analysis 6.1 Global Insulin Market Revenue Forecast and Analysis 6.1.1 Global Insulin Market, By Geography - Forecast and Analysis 6.1.2 Global Insulin Market - Market Potential Analysis, By Region 6.2 Company Analysis 6.2.1 Market Positioning of Key Players 6.2.2 Comparative Company Analysis 6.2.3 Growth Strategy Analysis 6.2.4 Performance Of Key Players 6.2.4.1 Novo Nordisk A/S 6.2.4.2 Sanofi 6.2.4.3 Eli Lily and Company 6.3 Customization Part 6.3.1 Market Share Analysis by Company 6.3.2 Market Share by Injectable GLPs 7. Insulin Market Analysis - By Type 7.1 Overview 7.2 Insulin Market Revenue Share, by Type (2021 and 2028) 7.3 Long Acting Insulin 7.3.1 Overview 7.3.2 Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.3.2.1 Levemir 7.3.2.1.1 Overview 7.3.2.1.2 Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.3.2.2 Lantus 7.3.2.2.1 Overview 7.3.2.2.2 Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.3.2.3 Basaglar 7.3.2.3.1 Overview 7.3.2.3.2 Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.3.2.4 Tresiba 7.3.2.4.1 Overview 7.3.2.4.2 Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4 Rapid Acting Insulins 7.4.1 Overview 7.4.2 Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4.2.1 Novolog 7.4.2.1.1 Overview 7.4.2.1.2 Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4.2.2 Humalog 7.4.2.2.1 Overview 7.4.2.2.2 Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4.2.3 Admelog 7.4.2.3.1 Overview 7.4.2.3.2 Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.4.2.4 Others 7.4.2.4.1 Overview 7.4.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5 Short Acting Insulins and Traditional Human Insulins 7.5.1 Overview 7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5.2.1 Novolin R 7.5.2.1.1 Overview 7.5.2.1.2 Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5.2.2 Humulin R 7.5.2.2.1 Overview 7.5.2.2.2 Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5.2.3 Insuman 7.5.2.3.1 Overview 7.5.2.3.2 Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.5.2.4 Others 7.5.2.4.1 Overview 7.5.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6 Concentrated Insulins and Combination Insulins 7.6.1 Overview 7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6.2.1 NovoMix 7.6.2.1.1 Overview 7.6.2.1.2 NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6.2.2 Ryzodeg 7.6.2.2.1 Overview 7.6.2.2.2 Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6.2.3 Xultophy 7.6.2.3.1 Overview 7.6.2.3.2 Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.6.2.4 Soliqua/Suliqua 7.6.2.4.1 Overview 7.6.2.4.2 Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.7 Biosimilar Insulins 7.7.1 Overview 7.7.2 Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.7.2.1 Insulin Glargine 7.7.2.1.1 Overview 7.7.2.1.2 Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.7.2.2 Human Insulin 7.7.2.2.1 Overview 7.7.2.2.2 Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.8 Glucagon-like peptide-1 (GLP-1) 7.8.1 Overview 7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.9 Pens and Needles 7.9.1 Overview 7.9.2 Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 7.10 Others 7.10.1 Overview 7.10.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million) 8. Global Insulin Market - Geographic Analysis 9. Impact of COVID-19 Pandemic on Global Insulin Market 9.1 North America: Impact Assessment of COVID-19 Pandemic 9.2 Europe: Impact Assessment of COVID-19 Pandemic 9.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic 9.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic 9.5 South and Central America: Impact Assessment of COVID-19 Pandemic 10. Insulin Market-Industry Landscape 10.1 Overview 10.2 Growth Strategies in the Insulin Market (%) 10.3 Organic Developments 10.3.1 Overview 10.4 Inorganic Developments 10.4.1 Overview 11. Company Profile 11.1 Eli Lilly and Company 11.1.1 Key Facts 11.1.2 Business Description 11.1.3 Products and Services 11.1.4 Financial Overview 11.1.5 SWOT Analysis 11.1.6 Key Developments 11.2 Novo Nordisk A/S 11.2.1 Key Facts 11.2.2 Business Description 11.2.3 Products and Services 11.2.4 Financial Overview 11.2.5 SWOT Analysis 11.2.6 Key Developments 11.3 Biocon 11.3.1 Key Facts 11.3.2 Business Description 11.3.3 Products and Services 11.3.4 Financial Overview 11.3.5 SWOT Analysis 11.3.6 Key Developments 11.4 WOCKHARDT 11.4.1 Key Facts 11.4.2 Business Description 11.4.3 Products and Services 11.4.4 Financial Overview 11.4.5 SWOT Analysis 11.4.6 Key Developments 11.5 Adocia 11.5.1 Key Facts 11.5.2 Business Description 11.5.3 Products and Services 11.5.4 Financial Overview 11.5.5 SWOT Analysis 11.5.6 Key Developments 11.6 GlaxoSmithKline plc. 11.6.1 Key Facts 11.6.2 Business Description 11.6.3 Products and Services 11.6.4 Financial Overview 11.6.5 SWOT Analysis 11.6.6 Key Developments 11.7 Sanofi 11.7.1 Key Facts 11.7.2 Business Description 11.7.3 Products and Services 11.7.4 Financial Overview 11.7.5 SWOT Analysis 11.7.6 Key Developments 11.8 Pfizer Inc. 11.8.1 Key Facts 11.8.2 Business Description 11.8.3 Products and Services 11.8.4 Financial Overview 11.8.5 SWOT Analysis 11.8.6 Key Developments 11.9 Merck & Co., Inc. 11.9.1 Key Facts 11.9.2 Business Description 11.9.3 Products and Services 11.9.4 Financial Overview 11.9.5 SWOT Analysis 11.9.6 Key Developments 11.10 Tonghua Dongbao Pharmaceutical Co., Ltd. 11.10.1 Key Facts 11.10.2 Business Description 11.10.3 Products and Services 11.10.4 Financial Overview 11.10.5 SWOT Analysis 11.10.6 Key Developments 11.11 BIGFOOT BIOMEDICAL, INC. 11.11.1 Key Facts 11.11.2 Business Description 11.11.3 Products and Services 11.11.4 Financial Overview 11.11.5 SWOT Analysis 11.11.6 Key Developments 12. Appendix For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

上市批准

2022-06-20

·PRNewswire

Insulin Market to Exceed US$ 30 Bn by 2031; Global Burden of Diabetes and Complications Propelling Adoption of Therapies, Observes TMR Report

Expansion of insulin therapies for type 1 diabetes and type 2 diabetes for pediatrics and adult patient populations presents abundant lucrative opportunities Drug makers witnessing sizable profit margins in premixed insulin analogs; launch of novel drugs to keep North America vastly lucrative ALBANY, N.Y., June 20, 2022 /PRNewswire/ -- The market demand for insulin therapies for better glycemic control in patients with diabetes mellitus has risen continuously over the years on the back of prevalence of the diseases. Technological advancements in human insulin analogs have resulted in widening their uptake in intensive insulin regimens, thus expanding streams of revenue of insulin market. The global valuation is projected to exceed US$ 30 Bn by 2031, advancing at CAGR of 4.3% from 2022 to 2031 (the forecast period). Pharmaceutical companies in the insulin market are likely to reap vast revenue gains from the relaxation in price-cap regulation on drugs including those used for insulin therapies. Nevertheless, number of generic drug manufacturers aiming to invest in biosimilars might hinder the revenue potential, observed the analysts of the TMR study on the insulin market. Furthermore, early uptake of insulin therapies in managing complications of diabetes is fueling insulin market expansion, notes the study. Increase in safety and efficacy of intensive insulin therapies has spurred investments in expanding the related drug pipeline especially in North America insulin market. In particular, premixed insulin analogs have gained popularity in such intensive therapies notably for managing type 2 diabetes mellitus. R&D on premixed insulin analogs has bolstered clinical support of their use in various complications of diabetes, and thus will propel investments by players to capitalize on the largest opportunity for insulin in adults and children. Request Brochure of Insulin Market Research Report – Key Findings of Insulin Market Therapy Launch of Safe and Efficacious Insulin Therapies for Diabetes Care Propelling Revenue Growth: Stakeholders in the insulin market are throwing their weight behind the growing clinical evidence on the safety and effectiveness of various human and modern insulin analogs in managing diabetes and the complications such as related to adverse cardiovascular events. Commercially available insulin preparations have been found to advance diabetes care with better glycemic control in diabetics, boosting the insulin market prospects. The growing trend of patient engagement in insulin therapies is favoring the growth dynamics of the insulin market. Undoubtedly, such approaches have helped physicians choose appropriate insulin regimens for their patients, thereby expanding the avenue for market players. Drug Manufacturers Benefit from Better Pricing Strategies: Drug makers are hopeful about the positive effect of the relaxed pricing cap regulations, observed the analysts in an in-depth study on the insulin market. Gradually the players have been able to choose a pricing strategy that benefits not only their profitably but also the interest of the patient population. Such strategies will stridently extend the canvas for insulin manufacturers and developers in the next few years. Request for Analysis of COVID-19 Impact on Insulin Market – Widespread Adoption of Premixed Insulin Analogs Generates Substantial Lucrative Business Opportunities: Companies have gained steady revenue streams from the rise in adoption of premixed insulin analogs—one of the key market segments in insulin. Especially in Asia Pacific, the demand is vast, noted the study in the global insulin market. The products can be customized to meet the individual needs of glycemic profiles of diabetics. Insulin Market: Key Drivers Per a finding in a study by International Diabetes Federation Diabetes, the prevalence of diabetes is projected to rise considerably between 2030 and 2045. Insulin therapies have been found to be especially effective in diabetes type-2 and its complications in managing the condition. Massive burden of the diseases has been propelling the evolution of the market. Rise in complications of both type 1 and type 2 diabetes and gestational diabetes is expected to steer the market prospects of insulin market. A number of products are in current developments and research pipeline to meet the needs of the patient population, notably in older adults. Get Exclusive PDF Sample Copy of Insulin Market Report – Insulin Market: Competition Landscape The insulin market is fairly consolidated in that the leading 10 players control majority of stakes, who are engaged in fierce competition among themselves to consolidate their shares. Some of the key players in the market include but not limited to B. Braun Melsungen AG, Biodel, Inc., Ypsomed AG, Becton, Dickinson and Company, Biocon Ltd., Julphar, Novo Nordisk A/S, Sanofi, Eli Lilly and Company, and Tonghua Dongbao. Make an Enquiry Before Buying – Insulin Market Segmentation Mode of Action Rapid-acting Short-acting Intermediate-acting Premixed Long-acting Source Modern Insulin Human Insulin Regions Covered North America Latin America Europe Latin America Middle East & Africa Countries Covered U.S. Canada Germany U.K. France Italy Spain China India Japan Australia & New Zealand Brazil Mexico GCC Countries South Africa Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Healthcare Industry Reports by Transparency Market Research: Smart Insulin Pens Market: Smart insulin pens are devices that are used to administer insulin for the treatment of diabetes. The global smart insulin pens market was valued at US$ 29.2 Mn in 2018 and is projected to reach US$ 70.4 Mn by 2027, expanding at a CAGR of 10.3% from 2019 to 2027. Insulin Delivery Devices Market: Increasing incidence of diabetes has been driving demand for minimal invasive devices for intravenous delivery of insulin in the body. This, in turn, is boosting insulin delivery devices market. Insulin Pen Needles Market: Prevalence of diseases such as diabetes, HIV and hepatitis will continue to contribute towards growth of the global insulin needles pen market significantly. Insulin Pumps Market: Mergers and acquisitions, alliances, and incorporation of advanced technologies are the other strategies employed by the key vendors in the global insulin pumps market. Smart Diabetes Management Market: Favourable reimbursements for digital diabetes management products and surge in the adoption of technologically-advanced products are key factors that are likely to boost the smart diabetes management market. Diabetes Devices Market: Increase in prevalence of diabetes, and increase in adoption of insulin pumps among type 1 diabetes patients are projected to drive the global diabetes devices market during the forecast period. Diabetes Drugs Market: Growing geriatric population across the world is one of the major factor fuelling demand for diabetes drugs. Elderly population is highly susceptible to certain health conditions such as blood pressure and diabetes. This, in turn, is contributing to growth of the diabetes drugs market. Diabetes Injection Pens Market: The global diabetes injection pens market is projected to grow at a rapid rate due to the rising population of diabetic patients worldwide and the consequent increase in management and awareness about the disease. About Us Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Us: Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] SOURCE Transparency Market Research

仿制药生物类似药并购

100 项与人胰岛素生物类似药(M J Biopharm Pvt Ltd.) 相关的药物交易

登录后查看更多信息